Emmaus Life SciencesEMMA -16.67% Quick Ratio is 0.06 as of Mar. 2026, which is 76% below its 10-year median of 0.25. The stock has 6 warning signs investors should review. Among 1,417 Biotechnology companies, Emmaus Life Sciences ranks worse than 97.81% on this metric.
Emmaus Life Sciences has a quick ratio of 0.06. It indicates that the company cannot currently fully pay back its current liabilities.
The historical rank and industry rank for Emmaus Life Sciences's Quick Ratio or its related term are showing as below:
EMMA'
s Quick Ratio Range Over the Past 10 Years
Min: 0.06 Med: 0.25 Max: 3.69
Current: 0.06
During the past 13 years, Emmaus Life Sciences's highest Quick Ratio was 3.69. The lowest was 0.06. And the median was 0.25.
EMMA's Quick Ratio is ranked worse than 97.81% of 1417
companies
in the Biotechnology industry
Industry Median: 3.6
vs EMMA: 0.06
Emmaus Life Sciences (OTCPK:EMMA) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Emmaus Life Sciences Quick Ratio Related Terms
Emmaus Life Sciences Quick Ratio Historical Data
* Premium members only.
The historical data trend for Emmaus Life Sciences's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Emmaus Life Sciences's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Emmaus Life Sciences Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Emmaus Life Sciences's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Emmaus Life Sciences's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Emmaus Life Sciences's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Emmaus Life Sciences (EMMA) has a Quick Ratio of 0.06 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Emmaus Life Sciences and its competitors. This is 76% below median its historical median of 0.25. Over the past decade, Emmaus Life Sciences' Quick Ratio has ranged from 0.06 to 3.69. According to the industry distribution chart, Emmaus Life Sciences ranks #1386 out of 1417 companies in the Biotechnology industry, placing it in the top 97.8%.
Is Emmaus Life Sciences' Quick Ratio too high?
Emmaus Life Sciences' current Quick Ratio of 0.06 is 76% below median its 10-year median of 0.25. Over the past 10 years, this metric has ranged from a low of 0.06 to a high of 3.69. The Biotechnology industry median Quick Ratio is 3.60. Emmaus Life Sciences' value of 0.06 is 98.3% below this industry median. Based on the distribution chart, Emmaus Life Sciences ranks #1386 out of 1417 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Emmaus Life Sciences' Quick Ratio compare to CERO and AGTX?
According to the Biotechnology industry distribution chart, Emmaus Life Sciences ranks #1386 out of 1417 companies for Quick Ratio. This places Emmaus Life Sciences in the lower half of its industry. The industry median Quick Ratio is 3.60. Emmaus Life Sciences' value of 0.06 is 98.3% below this benchmark. Historically, Emmaus Life Sciences' own Quick Ratio has ranged from 0.06 to 3.69 over the past decade. While the company's 10-year median is 0.25 vs. the industry median of 3.60, Emmaus Life Sciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,417 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Emmaus Life Sciences's current Quick Ratio of 0.06 is 98.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Emmaus Life Sciences and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Emmaus Life Sciences's current Quick Ratio is 0.06, which is 76% below median its own 10-year median of 0.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Emmaus Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Emmaus Life Sciences (EMMA) is currently considered Fairly Valued. The stock's GF Value™ is $0.01, compared to a current price of $0.01 — trading right at its estimated fair value. The current Quick Ratio is 0.06, which is 76% below median its 10-year median of 0.25 and 98.3% below the Biotechnology industry median of 3.60. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Emmaus Life Sciences (EMMA), the current Quick Ratio is 0.06 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Emmaus Life Sciences Inc is a commercial-stage biopharmaceutical company engaged in the discovery, development, marketing and sales of the Company's product Endari (prescription grade L-glutamine oral powder), to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients five years of age and older. Endari is reimbursable by the Centers for Medicare and Medicaid Services, and every state provides coverage for Endari for outpatient prescriptions to all eligible Medicaid enrollees within their state Medicaid programs. Endari is also reimbursable by many commercial payors.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EMMA has been successfully added to your 